If you have evaporative dry eye, you will be familiar with the frustration of traditional artificial tears. You put a drop in, it provides a few minutes of relief, and then the eyes start to feel irritated again.
This happens because standard artificial tears are predominantly water. If your tear film is missing its protective top layer of oil, adding more water doesn’t help much.
Enter MIEBO®/NovaTears® (perfluorohexyloctane ophthalmic solution). FDA-approved, it represents a massive paradigm shift in how we treat the ocular surface. It is the first and only prescription eye drop approved for dry eye disease that directly targets tear evaporation.
What Makes MIEBO Unique?
Aside from it being preservative-free, Miebo is one of a kind eye drop.
1. It is 100% Water-Free MIEBO contains exactly one ingredient: perfluorohexyloctane. There is zero water in this formulation. Because bacteria and fungi need water to grow, the absence of water means no preservatives are needed.
2. Low Surface Tension Perfluorohexyloctane is a unique compound called a semi-fluorinated alkane. It has an incredibly low surface tension, much lower than water. When you instill a drop, it instantly and completely spreads across the entire surface of your eye. It essentially acts as a synthetic substitute for your missing meibomian gland oils, creating a liquid blanket that traps your natural underlying tears and prevents them from evaporating.
3. A Micro-Drop Because of that low surface tension, a single drop of MIEBO is tiny, about one-quarter the size of a standard water-based eye drop.
Breaking Down the GOBI and MOJAVE Trials
When a pharmaceutical company claims a drug works, the FDA demands proof in the form of massive, tightly controlled clinical trials. For MIEBO, these were the GOBI and MOJAVE trials.
Here is what those studies looked at, and what they proved over their 57-day duration involving over 1,200 adult patients with a history of dry eye disease:
1. The primary objective sign the researchers tracked was Total Corneal Fluorescein Staining (tCFS). This is when we put in the orange dye to highlight microscopic areas of dead or damaged cells on your cornea.
The Result: Patients using MIEBO showed a statistically significant reduction in tCFS compared to the saline control group at Day 57. This proves that by stopping evaporation, MIEBO heals the corneal surface.
(A) Mean (SD) CFB in tCFS is –2.1 (2.5) among the total population (n=208) at week 52. (B) Mean (SD) CFB in VAS eye dryness score is -33.7 (28.6) among the total population (n=208) at week 52. (https://www.miebo.com/)
2. Healing the cells is great, but a drug is only successful if the patient actually feels better. Researchers used an Eye Dryness Score (Visual Analog Scale - VAS) to measure subjective symptom relief.
The Result: MIEBO users reported a significant reduction in their eye dryness symptoms compared to the control group.
3. One of the most frustrating aspects of traditional prescription dry eye drops (like immunomodulators) is that they can take weeks to months to kick in. In both GOBI and MOJAVE, patients were evaluated early at the Day 15 mark.
The Result: Significant improvements in both signs (corneal healing) and symptoms (patient comfort) were observed as early as Day 15, and those improvements were sustained through the end of the 57-day trials.
MIEBO also demonstrated 4x improvement vs control in CENTRAL CFS at Day 57, which was a secondary endpoint
(https://www.miebo.com/)
What This Means For You (And Patients)
If you have been diagnosed with Meibomian Gland Dysfunction (MGD) or evaporative dry eye, MIEBO is a highly logical therapeutic option. However, there are a few practical things you must know before using it:
The Drop Feels Different: Because it is a tiny, water-free drop, it does not have the heavy, cooling splash of a traditional eye drop. Many patients initially think they missed their eye because the drop is so small and light. Some patients find it useful to instill the drop in front of a mirror to ensure if goes into the eyes.
No Blurring: Unlike other lipid-based drops or thick gels, MIEBO’s unique chemical structure means it typically does not cause the severe blurred vision.
Contact Lens Wear: It is not compatible with contact lens wear, so you will need to remove them before using MIEBO. Ideally, wait at least 15 minutes before reinserting them.
Cost and Tariffs: Because MIEBO is a novel, patented prescription medication, it falls squarely into the high-tier pricing category. Costs usually depend on your insurance coverage and potential trade tariffs on imported pharmaceuticals (US Pharma Tariffs: The Impact on Dry Eye Medications).
